Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold. 2017

Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, PR China.

Four series of Sorafenib derivatives bearing pyrazole scaffold (8a-m, 9a-c, 10a-e and 11a) were synthesized and characterized by NMR and MS. All of the target compounds were evaluated for the cytotoxicity against A549, HepG2, MCF-7, and PC-3 cancer cell lines and some selected compounds were further evaluated for the activity against VEGFR-2/KDR, BRAF, CRAF, c-Met, EGFR and Flt-3 kinases. Compounds 8b and 8i were more active than that of compounds 8h, 9a, especially the IC50 value of compounds 8b on VEGFR-2 kinase was 0.56μM. And compound 8b exhibited moderate to good activity toward c-Met and showed moderate to no activity against CRAF, c-Met, EGFR, Flt-3 kinases. Eleven of the target compounds exhibited moderate to good antitumor activities. The most promising compound 8b showed strong antitumor activities against A549, HepG2 and MCF-7 cell lines with IC50 values of 2.84±0.78μM, 1.85±0.03μM and 1.96±0.28μM, which were equivalent to Sorafenib (2.92±0.68μM, 3.44±0.50μM and 3.18±0.18μM). Structure-activity relationships (SARs) and docking studies indicated that the pyrazole scaffolds exerted key effect on antitumor activities of target compounds. Substitutions of aryl group at C-3 positions had a significant impact on the antitumor activities, and 3-Br substitution produced the best potency.

UI MeSH Term Description Entries
D008856 Microscopy, Fluorescence Microscopy of specimens stained with fluorescent dye (usually fluorescein isothiocyanate) or of naturally fluorescent materials, which emit light when exposed to ultraviolet or blue light. Immunofluorescence microscopy utilizes antibodies that are labeled with fluorescent dye. Fluorescence Microscopy,Immunofluorescence Microscopy,Microscopy, Immunofluorescence,Fluorescence Microscopies,Immunofluorescence Microscopies,Microscopies, Fluorescence,Microscopies, Immunofluorescence
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D010671 Phenylurea Compounds Compounds that include the amino-N-phenylamide structure. Phenylcarbamides,Phenylurea Derivatives,Compounds, Phenylurea,Derivatives, Phenylurea
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077157 Sorafenib A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy. 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate,BAY 43-9006,BAY 545-9085,BAY-545-9085,BAY-673472,Nexavar,Sorafenib N-Oxide,Sorafenib Tosylate,BAY 43 9006,BAY 439006,BAY 545 9085,BAY 5459085,BAY 673472,BAY5459085,Sorafenib N Oxide
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
December 1999, Chemical & pharmaceutical bulletin,
Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
July 2021, Bioorganic & medicinal chemistry letters,
Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
December 2017, Natural products and bioprospecting,
Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
September 2017, Molecules (Basel, Switzerland),
Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
September 2018, Drug development research,
Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
February 2005, Chemical & pharmaceutical bulletin,
Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
August 2023, Chemistry & biodiversity,
Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
June 2016, European journal of medicinal chemistry,
Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
November 2012, Bioorganic & medicinal chemistry letters,
Min Wang, and Shan Xu, and Huajun Lei, and Caolin Wang, and Zhen Xiao, and Shuang Jia, and Jia Zhi, and Pengwu Zheng, and Wufu Zhu
September 2018, European journal of medicinal chemistry,
Copied contents to your clipboard!